

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00455)

SUPPLEMENTAL ANNOUNCEMENT REGARDING ANNUAL GENERAL MEETING

Reference is made to the Notice of Annual General Meeting dated 25 July 2022 (the “AGM Notice”) of Tianda Pharmaceuticals Limited (the “Company”).

The annual general meeting of the Company (the “AGM”) will be held as originally scheduled, at Suites 2405-2410, 24th Floor, CITIC Tower, No. 1 Tim Mei Avenue, Central, Hong Kong on Thursday, 25 August 2022 at 10:30 a.m. for the purpose of considering and, if thought fit, approving the resolutions set out in the AGM Notice.

The purpose of this announcement is to give shareholders of the Company (the “Shareholders”) further details on the precautionary measures to be taken by the Company to prevent and control the spread of COVID-19 at the AGM.

Taking into account the recent development in relation to the COVID-19 outbreak, the Company will implement the preventive and control measures at the meeting venue of the AGM. Reference should be made to the circular of the Company dated 25 July 2022 (the “Circular”) for details. In addition to the preventive and control measures set out in the Circular, attendees are required to do a Rapid Antigen Test (the “RAT”) for COVID-19 on the date of the AGM before they go to the AGM venue. **Attendees will be requested to show a photo of their negative RAT result at the entrance of the AGM venue. If any attendee gets a positive RAT result or suspects himself/herself is infected with COVID-19, he/she should not attend the AGM physically.**

The Company reserves the right in refusing the entry of any person to the venue of the AGM to the extent permitted by the applicable laws and regulations.

In light of the outbreak of COVID-19, the Company strongly encourages the Shareholders to exercise their right to vote at the AGM by appointing the chairman of the meeting as their meeting proxy to vote on the relevant resolution(s) at the AGM as an alternative to attending the AGM physically and contacting the Company for questions to management, if any.

As the COVID-19 outbreak continues to develop, the Company will closely monitor the situation and reserves the right to take further measures or make any changes to the arrangement of the AGM as appropriate at short notice in order to minimise any risk to the Shareholders and others attending the AGM and to comply with any requirements or recommendations of any government authorities from time to time.

By order of the Board
Tianda Pharmaceuticals Limited
FANG Wen Quan
Chairman and Managing Director

Hong Kong, 12 August 2022

As at the date of this announcement, the executive directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive directors are Mr. SHEN Bo and Mr. FENG Quanming; and the independent non-executive directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.